Feró, O., Szabóné, V., Nagy, É., Karányi, Z., Sipos, É., Engelhardt, J., Török, N., Balogh, I., Vető, B., Liko, I., Fóthi, Á., Szabó, Z., Halmos, G., Vécsei, L., Arányi, T., Székvölgyi, L.: DNA methylome, R-loop and clinical exome profiling of patients with sporadic amyotrophic lateral sclerosis.
Sci Data. 11 (1), 1-12, 2024.

Steli, Á., Vass, A., Király, J., Halmos, G., Szabó, Z.: Examination of Novel Biomarkers in Kidney Cancers.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024 (Kölcsey Center, Debrecen, Hungary) : Abstracts. Kiadta: a Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, Budapest, , 2024.

Juhász, É., Szabó, Z., Schally, A., Király, J., Fodor, P., Kónya, G., Dezső, B., Szabó, E., Halmos, G., Kiss, C.: Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in a Cohort of Hungarian Pediatric Patients with Hematological and Oncological Disorders: a Pilot Study.
Int. J. Mol. Sci. 25 (16), 1-12, 2024.

Király, J., Szabó, E., Fodor, P., Vass, A., Choudhury, M., Gesztelyi, R., Szász, C., Flaskó, T., Dobos, N., Zsebik, B., Steli, Á., Halmos, G., Szabó, Z.: Expression of hsa-miRNA-15b, -99b, -181a and Their Relationship to Angiogenesis in Renal Cell Carcinoma.
Biomedicines. 12 (7), 1-18, 2024.

Dobos, N., Kónya, G., Szabó, Z., Király, J., Szegedi, K., Halmos, G.: Expression of Indoleamine 2,3-Dioxygenase and PTEN in Human Renal Carcinoma.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024 / Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, Debrecen, 248, 2024.

Szabó, Z., Király, J., Szegedi, K., Fodor, P., Vass, A., Szabó, E., Deák, R., Dobos, N., Zsebik, B., Steli, Á., Halmos, G.: Expression of miRNAs and Angiogenesis Markers in Kidney Cancer.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024 (Kölcsey Center, Debrecen, Hungary) : Abstracts. Kiadta: a Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, Budapest, , 2024.

Vass, A., Deák, R., Király, J., Steli, Á., Szabó, Z., Halmos, G.: Expression of Various Multidrug Transporters in Human Kidney Cancer.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024 (Kölcsey Center, Debrecen, Hungary) : Abstracts. Kiadta: a Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, Budapest, , 2024.

Gomena, J., Modena, D., Cordella, P., Vári, B., Ranđelović, I., Borbély, A., Bottani, M., Vári-Mező, D., Halmos, G., Juhász, É., Steinkühler, C., Tóvári, J., Mező, G.: In vitro and in vivo evaluation of Bombesin-MMAE conjugates for targeted tumour therapy.
Eur. J. Med. Chem. 277 1-13, 2024.

Farkasinszky, G., Péli-Szabó, J., Károlyi, P., Rácz, S., Dénes, N., Papp, T., Király, J., Szabó, Z., Kertész, I., Mező, G., Halmos, G., Képes, Z., Trencsényi, G.: In Vivo Imaging of Acute Hindlimb Ischaemia in Rat Model: a Pre-Clinical PET Study.
Pharmaceutics. 16 (4), 1-14, 2024.

Fodor, P., Király, J., Szabó, Z., Halmos, G., Zsebik, B.: Quercetin Treatment of Metastatic Uveal Melanoma Cell Line.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024. Kiadta: a Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, 2024, 272, 2024.

Sona, S., Fodor, P., Halmos, G., Zsebik, B.: Response of p53 and Nf-kB to Polyphenol Quercetin Treatment in Uveal melanoma Cells.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024 / Magyar Gyógyszerésztudományi Társaság, Magyar Gyógyszerésztudományi Társaság, Debrecen, 412, 2024.

Szabó, I., Biri-Kovács, B., Vári, B., Ranđelović, I., Vári-Mező, D., Juhász, É., Halmos, G., Bősze, S., Tóvári, J., Mező, G.: Targeting the Melanocortin 1 Receptor in Melanoma: biological Activity of alpha-MSH-Peptide Conjugates.
Int. J. Mol. Sci. 25 (2), 1-21, 2024.

Király, J., Szabó, E., Vass, A., Deák, R., Halmos, G., Szabó, Z.: The effect of Shikonin on the expression of apoptosis related miRNAs and their putative targets in human kidney cancer cells.
In: Congressus Pharmaceuticus Hungaricus XVII. and EUFEPS Annual Meeting 2024. Ed.: Éva Szökő, María Blanco-Prieto, Magyar Gyógyszerésztudományi Társaság, Debrecen, 308, 2024.

Király, J., Szabó, E., Vass, A., Szegedi, K., Szenthe, K., Halmos, G., Szabó, Z.: A shikonin hatása az apoptózisban szerepet játszó miRNS-sek és azon targetjeinek expressziójára humán vesedaganatos sejtvonalakon.
In: Membrán-Transzport konferencia : programfüzet. Kiadta: a Pécsi Tudományegyetem, Pécsi Tudományegytem, Pécs, 82, 2023.

Csikos, C., Képes, Z., Fekete, A., Vágner, A., Nagy, G., Gyuricza, B., Arató, V., Kárpáti, L., Mándity, I., Bruchertseifer, F., Halmos, G., Szikra, D., Trencsényi, G.: Evaluation of the therapeutic efficacy of 213Bi-labelled DOTA-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model.
Int. J. Pharm. 644 1-9, 2023.

Trencsényi, G., Enyedi, K., Mező, G., Halmos, G., Képes, Z.: NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: a Preclinical Review.
Int. J. Mol. Sci. 24 (16), 1-34, 2023.

Szegedi, K., Szabó, Z., Kállai, J., Király, J., Szabó, E., Bereczky, Z., Juhász, É., Dezső, B., Szász, C., Zsebik, B., Flaskó, T., Halmos, G.: Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors.
J Clin Med. 12 (13), 1-18, 2023.

Trencsényi, G., Halmos, G., Képes, Z.: Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: a Review of Preclinical Studies.
Cancers (Basel). 15 (18), 1-22, 2023.

Király, J., Szabó, E., Fodor, P., Fejes, Z., Nagy, B., Juhász, É., Vass, A., Choudhury, M., Kónya, G., Halmos, G., Szabó, Z.: Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways.
Molecules. 28 (18), 1-22, 2023.

Halmos, G., Szabó, Z., Juhász, É., Schally, A.: Signaling mechanism of growth hormone-releasing hormone receptor.
In: Hormone Receptors: Structures and Functions / Gerald Litwack, Academic Press Inc Elsevier Science, San Diego, 1-26, 2023, (Vitamins and Hormones, ISSN 0083-6729 ; 123.) ISBN: 9780443134555

Vass, A., Szabó, Z., Király, J., Fodor, P., Steli, Á., Szabó, E., Szegedi, K., Halmos, G.: Transzporterek expressziójának vizsgálata humán vesekarcinómában.
In: Membrán-Transzport konferencia : programfüzet. Kiadta: a Pécsi Tudományegyetem, Pécsi Tudományegytem, Pécs, 121, 2023.

Steli, Á., Király, J., Szász, C., Vass, A., Szegedi, K., Szabó, Z., Halmos, G.: Újszerű biomarkerek vizsgálata vesetumorokban.
In: Membrán-Transzport konferencia : programfüzet. Kiadta: a Pécsi Tudományegyetem, Pécsi Tudományegytem, Pécs, 107, 2023.

Király, J., Fodor, P., Szenthe, K., Szabó, E., Flaskó, T., Szegedi, K., Zsebik, B., Szász, C., Halmos, G., Szabó, Z.: Angiogenezismarkerek és miRNS-ek kapcsolatának vizsgálata humán vesekarcinómában.
Magyar Onkol. 66 249-250, 2022.

Schuster, S., Juhász, É., Halmos, G., Neundorf, I., Gennari, C., Mező, G.: Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
Int. J. Mol. Sci. 23 (9), 1-18, 2022.

Fodor, P., Király, J., Szabó, Z., Halmos, G., Zsebik, B.: Effect of quercetin on metastatic uveal melanoma cell line.
In: Biotechnology at the University of Debrecen - 2022 International Symposium Abstract Book / Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Debrecen, 71, 2022. ISBN: 9789634904670

Szabó, Z., Juhász, É., Schally, A., Dezső, B., Huga, S., Hernádi, Z., Halmos, G., Kiss, C.: Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: novel Therapeutic Approaches.
Molecules. 27 (9), 1-13, 2022.

Kónya, G., Szabó, Z., Király, J., Dobos, N., Zsebik, B., Szegedi, K., Halmos, G.: Expression of Indoleamine 2,3-Dioxygenase (IDO) and Pten in Human Renal Carcinoma.
In: Biotechnology at the University of Debrecen - 2022 International Symposium Abstract Book / Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Debrecen, 75, 2022.

Szabó, Z., Király, J., Kónya, G., Szegedi, K., Halmos, G.: Expression of miRNAs and Angiogenesis Markers in Human Kidney Cancer.
In: Biotechnology at the University of Debrecen - 2022 International Symposium Abstract Book / Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Debrecen, 26, 2022.

Király, J., Fodor, P., Szenthe, K., Szabó, E., Flaskó, T., Szegedi, K., Zsebik, B., Szász, C., Halmos, G., Szabó, Z.: miRNS-ek és angiogenezis markerek kapcsolatának vizsgálata humán vese karcinómában.
In: Abstract book of the 6th International Cholnoky Symposium. Kiadta: a Pécsi Tudományegyetem, Pécsi Tudományegyetem, Pécs, 10, 2022.

Fodor, P., Király, J., Szabó, Z., Halmos, G., Zsebik, B.: Quercetin hatásának vizsgálata metasztatikus uveális melanóma sejtvonalon.
Magyar Onkol. 66 249, 2022.

Király, J., Szabó, E., Fodor, P., Zsebik, B., Kónya, G., Vass, A., Halmos, G., Szabó, Z.: Shikonin inhibits proliferation of human kidney cancer cells through induction of apoptosis.
In: Biotechnology at the University of Debrecen - 2022 International Symposium Abstract Book. Ed.: Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Faculty of Science and Technology, Department of Molecular Biotechnology and Microbiology, Institute of Biotechnology and Faculty of Agricultural and Food Sciences and Enviromental Management, Central Laboratory of Agricultural and Food Products, Debrecen, 74, 2022. ISBN: 9789634904670

Cai, R., Zhang, X., Wang, H., Cui, T., Halmos, G., Sha, W., He, J., Popovics, P., Vidaurre, I., Zhang, C., Mirsaeidi, M., Schally, A.: Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Peptides. 150 1-13, 2022.

Fodor, P., Király, J., Szabó, Z., Halmos, G., Zsebik, B.: The potential applicability of quercetin in the treatment of uveal melanoma tumour metastases.
In: Abstract book of the 6th International Cholnoky Symposium. Kiadta: a Pécsi Tudományegyetem, Pécsi Tudományegyetem, Pécs, 25, 2022.

Papp, T., Winkler-Ferenczi, Z., Szilágyi, B., Petró, M., Varga, A., Kókai, É., Berényi, E., Oláh, G., Halmos, G., Szűcs, P., Mészár, Z.: Ultrasound Used for Diagnostic Imaging Facilitates Dendritic Branching of Developing Neurons in the Mouse Cortex.
Front. Neurosci. 162022.

Fodor, P., Molnár-Fodor, K., Zsebik, B., Szabó, Z., Dobos, N., Schally, A., Halmos, G.: Angiogenezisgátló célzott terápiás VEGF-inhibitor és citotoxikus peptidhormon-analóg kombinált alkalmazásának vizsgálata uvealis melanomában in vitro.
Magyar Onkol. 65 (Suppl.), 19, 2021.

Király, J., Halmos, G., Szabó, Z.: A növényi alapú shikonin onkogén jellegű miRNS-expressziónak vizsgálata humán vesedaganat-sejtvonalakon Nanostring technológiával.
Magyar Onkol. 65 (Suppl.1), 29, 2021.

Kónya, G., Király, J., Dobos, N., Szegedi, K., Zsebik, B., Fodor, P., Szabó, Z., Halmos, G.: Az indolamin-2,3-dioxigenáz (IDO) és a PTEN expressziójának vizsgálata vesetumorokban és humán vesedaganat-sejtvonalakon.
Magyar Onkol. 65 (Suppl.1), 34, 2021.

Kónya, G., Szabó, Z., Király, J., Dobos, N., Zsebik, B., Szegedi, K., Halmos, G.: Expression of indoleamine 2,3-dioxygenase (IDO) and PTEN in human renal carcinoma.
In: Medical Conference for PhD Students and Experts of Clinical Sciences, Book of Abstracts / publ. by Doctoral Student Association of the University of Pécs, University of Pécs, Pécs, 103, 2021.

Szabó, Z., Dezső, B., Molnár-Fodor, K., Szegedi, K., Flaskó, T., Szabó, E., Oláh, G., Sipos, É., Dobos, N., Gardi, J., Schally, A., Halmos, G.: Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer.
Molecules. 26 (5), 1-14, 2021.

Király, J., Szabó, E., Fejes, Z., Nagy, B., Fodor, P., Kónya, G., Halmos, G., Szabó, Z.: Shikonin inhibits proliferation of human kidney cancer cells through induction of apoptosis.
In: Medical Conference for PhD Students and Experts of Clinical Sciences, Book of Abstracts / publ. by Doctoral Student Association of the University of Pécs, University of Pécs, Pécs, 102, 2021.

Harda, K., Halmos, G.: Amitől minden nő retteg: policisztás ovárium szindróma.
Gyógyszerészet. 64 (4), 214-218, 2020.

Molnár-Fodor, K., Sipos, É., Dobos, N., Nagy, J., Steiber, Z., Méhes, G., Dull, K., Székvölgyi, L., Schally, A., Halmos, G.: Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma.
Life (Basel). 10 (12), 1-15, 2020.

Molnár-Fodor, K., Dobos, N., Nagy, J., Méhes, G., Halmos, G.: Correlations between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma.
In: 4th National Conference of Young Biotechnologists : Abstract Book "FIBOK 2020" / publ. University of Debrecen, University of Debrecen, Debrecen, 56, 2020.

Király, J., Szabó, E., Fejes, Z., Nagy, B., Fodor, P., Szabó, Z., Halmos, G.: Effect of Shikonin on the Expression of Oncogenic miRNAs in Human Renal Cancer Cell Lines.
In: 4th National Conference of Young Biotechnologists : Abstract Book "FIBOK 2020" / publ. University of Debrecen, University of Debrecen, Debrecen, 58, 2020.

Harda, K., Szabó, Z., Juhász, É., Dezső, B., Kiss, C., Schally, A., Halmos, G.: Expression of Somatostatin Receptor Subtypes (SSTR-1-SSTR-5) in Pediatric Hematological and Oncological Disorders.
Molecules. 25 (23), 1-14, 2020.

Molnár-Fodor, K., Dobos, N., Schally, A., Steiber, Z., Oláh, G., Sipos, É., Székvölgyi, L., Halmos, G.: The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.
Oncotarget. 11 (2), 175-187, 2020.

Molnár-Fodor, K., Dobos, N., Schally, A., Steiber, Z., Halmos, G.: The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.
In: 4th National Conference of Young Biotechnologists : Abstract Book "FIBOK 2020" / publ. University of Debrecen, University of Debrecen, Debrecen, 50, 2020.

Szabó, E., Szabó, Z., Fejes, Z., Nagy, B., Harda, K., Szegedi, K., Halmos, G.: A shikonin humán vesedaganat-sejtvonalakra kifejtett apoptotikus hatása.
Magyar Onkol. 63 (Suppl1), 63, 2019.

Halász, L., Karányi, Z., Boros-Oláh, B., Kuik-Rózsa, T., Sipos, É., Nagy, É., Mosolygó, Á., Türk-Mázló, A., Rajnavölgyi, É., Halmos, G., Székvölgyi, L.: Corrigendum: RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases.
Genome Res. 29 (1), 157-157, 2019.

Boros-Oláh, B., Dobos, N., Hornyák, L., Szabó, Z., Karányi, Z., Halmos, G., Roszik, J., Székvölgyi, L.: Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy.
DNA Repair. 84 1-10, 2019.

Halmos, G., Dobos, N., Juhász, É., Szabó, Z., Schally, A.: Hypothalamic Releasing Hormones.
In: Hormonal signaling in biology and medicine : comprehensive modern endocrinology. Ed.: by Gerald Litwack, Academic Press, London, 43-68, 2019. ISBN: 9780128138144

Murányi, J., Varga, A., Gyulavári, P., Pénzes, K., Németh, C., Csala, M., Pethő, L., Csámpai, A., Halmos, G., Peták, I., Vályi-Nagy, I.: Novel Crizotinib-GnRH conjugates revealed the significance of lysosomal trapping in GnRH-based drug delivery systems.
Int. J. Mol. Sci. 20 (22), 1-23, 2019.

Pethő, L., Murányi, J., Pénzes, K., Gurbi, B., Brauswetter, D., Halmos, G., Csík, G., Mező, G.: Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers.
Int. J. Mol. Sci. 20 (20), 1-17, 2019.

Harda, K., Szabó, Z., Szabó, E., Flaskó, T., Halmos, G.: Szomatosztatinreceptorok expressziójának vizsgálata vesetumorokban és humán vesedaganat-sejtvonalakon.
Magyar Onkol. 63 (Suppl1), 62, 2019.

Sipos, É., Dobos, N., Rózsa, D., Molnár-Fodor, K., Oláh, G., Szabó, Z., Székvölgyi, L., Schally, A., Halmos, G.: Characterization of Luteinizing hormone-releasing hormone (LH-RH-I) receptor type I as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.
OncoTargets Ther. 11 933-941, 2018.

Schuster, S., Biri-Kovács, B., Szeder, B., Buday, L., Gardi, J., Szabó, Z., Halmos, G., Mező, G.: Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.
Pharmaceutics. 10 (4), 1-19, 2018.

Oláh, G., Dobos, N., Vámosi, G., Szabó, Z., Sipos, É., Molnár-Fodor, K., Harda, K., Schally, A., Halmos, G.: Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Eur. J. Pharm. Sci. 123 371-376, 2018.

Harda, K., Szabó, Z., Szabó, E., Oláh, G., Molnár-Fodor, K., Szász, C., Méhes, G., Schally, A., Halmos, G.: Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.
Molecules. 23 (7), 1-13, 2018.

Schuster, S., Biri-Kovács, B., Szeder, B., Farkas, V., Buday, L., Szabó, Z., Halmos, G., Mező, G.: Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
Beilstein J. Org. Chem. 14 756-771, 2018.

Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., Székvölgyi, L.: The role of indoleamine-2,3-dioxygenase (IDO) in cancer development, diagnostics, and therapy.
Front. Immunol. 9 (151), 1-8, 2018.

Sipos, É., Dull, K., Treszl, A., Steiber, Z., Méhes, G., Dobos, N., Molnár-Fodor, K., Oláh, G., Székvölgyi, L., Schally, A., Halmos, G.: Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma.
Oncol. Rep. 37 1927-1934, 2017.

Halász, L., Karányi, Z., Boros-Oláh, B., Kuik-Rózsa, T., Sipos, É., Nagy, É., Mosolygó, Á., Türk-Mázló, A., Rajnavölgyi, É., Halmos, G., Székvölgyi, L.: RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases.
Genome Res. 27 1063-1073, 2017.

Zarándi, M., Cai, R., Kovács, M., Popovics, P., Szalontay, L., Cui, T., Sha, W., Jászberényi, M., Varga, J., XianYang, Z., Block, N., Rick, F., Halmos, G., Schally, A.: Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
Peptides. 89 60-70, 2017.

Szegedi, K., Szabó, Z., Flaskó, T., Halmos, G.: A mikroRNS-ek jelenléte vesetumorokban és lehetséges diagnosztikai-prognosztikai szerepük.
Magyar Urol. 18 (4), 183-188, 2016.

Szabó, Z., Szegedi, K., Gombos, K., Mahua, C., Flaskó, T., Harda, K., Halmos, G.: Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.
Urol. Oncol.-Semin. Orig. Investig. 34 (12), 533, 2016.

Szabó, I., Bősze, S., Orbán, E., Sipos, É., Halmos, G., Kovács, M., Mező, G.: Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
J. Pept. Sci. 21 (5), 426-435, 2015.

Halmos, G., Bácskay, I., Harda, K.: Gyógyszerészi gondozási példák.
Debreceni Egyetem, Debrecen, 120 p., 2015.

Halmos, G., Bácskay, I., Harda, K.: Pharmaceutical Care Practical Study Notes.
Debreceni Egyetem, Debrecen, 129 p., 2015.

Halmos, G.: Selected chapters of pharmaceutical bioanalytical methods.
Debreceni Egyetem, Debrecen, 126 p., 2015.

Halmos, G.: Válogatott fejezetek a gyógyszerészi bioanalitikából.
Debreceni Egyetem, Debrecen, 137 p., 2015.

Steiber, Z., Sipos, É., Dull, K., Halmos, G., Méhes, G., Treszl, A.: Aneuploidy of chromosome 3 and 4 in human uveal melanomas detected by fluorescence in situ hybridization.
Invest. Ophthalmol. Vis. Sci. 55 6444, 2014.

Mezey, G., Treszl, A., Schally, A., Block, N., Vízkeleti, L., Juhász, A., Klekner, Á., Nagy, J., Balázs, M., Halmos, G., Bognár, L.: Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.
J. Cancer Res. Clin. Oncol. 140 (10), 1641-1649, 2014.

Steiber, Z., Halmos, G., Cserháti, Z., Treszl, A.: Expression of stem cell markers in human uveal melanoma.
Acta Ophthalmol. 91 s252, 2013.

Oláh, G., Steiber, Z., Halmos, G.: Iránytű műkönnyekhez: gyógyszerészeknek.
Gyógyszerészet. 57 (2), 77-80, 2013.

Szepesházi, K., Schally, A., Block, N., Halmos, G., Nadji, M., Szalontay, L., Vidaurre, I., Abi-Chaker, A., Rick, F.: Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108.
Oncotarget. 4 (5), 751-760, 2013.

Rick, F., Abi-Chaker, A., Szalontay, L., Perez, R., Jászberényi, M., Jayakumar, A., Shamaladevi, N., Szepesházi, K., Vidaurre, I., Halmos, G., Krishan, A., Block, N., Schally, A.: Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Proc. Natl. Acad. Sci. U.S.A. 110 (7), 2617-2622, 2013.

Treszl, A., Steiber, Z., Schally, A., Block, N., Dezső, B., Oláh, G., Rózsa, B., Molnár-Fodor, K., Buglyó, A., Gardi, J., Berta, A., Halmos, G.: Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.
Oncotarget. 4 (10), 1721-1728, 2013.

Cai, R., Schally, A., Cui, T., Szalontay, L., Halmos, G., Sha, W., Kovács, M., Jászberényi, M., He, J., Rick, F., Popovics, P., Kanashiro-Takeuchi, R., Hare, J., Block, N., Zarándi, M.: Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.
Peptides. 52C 104-112, 2013.

Hegedűs, R., Manea, M., Orbán, E., Szabó, I., Kiss, É., Sipos, É., Halmos, G., Mező, G.: Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Eur. J. Med. Chem. 56 155-165, 2012.

Stangelberger, A., Schally, A., Rick, F., Varga, J., Baker, B., Zarándi, M., Halmos, G.: Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Prostate. 72 (5), 555-565, 2012.

Oláh, G., Steiber, Z., Halmos, G.: Mi folyik a műkönnyekkel?.
Gyógyszerészet. 56 (11), 663-666, 2012.

Klukovits, A., Schally, A., Szalontay, L., Vidaurre, I., Papadia, A., Zarándi, M., Varga, J., Block, N., Halmos, G.: Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Cancer. 118 (3), 670-680, 2012.

Szepesházi, K., Schally, A., Rick, F., Block, N., Vidaurre, I., Halmos, G., Szalontay, L.: Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Anti-Cancer Drugs. 23 (9), 906-913, 2012.

Szepesházi, K., Schally, A., Keller, G., Block, N., Benten, D., Halmos, G., Szalontay, L., Vidaurre, I., Jászberényi, M., Rick, F.: Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Oncotarget. 3 (7), 686-699, 2012.

Schally, A., Halmos, G.: Targeting to Peptide Receptors.
In: Drug Delivery in Oncology : From Basic Research to Cancer Therapy (Vol.3). Szerk.: Kratz Felix, Senter Peter, Steinhagen Henning, Wiley-VCH, Weinheim, 1219-1262, 2012. ISBN: 9783527328239

Aigner, Z., Bácskay, I., Blazsó, G., Botz, L., Dévay, A., Doró, P., Dredán, J., Fehér, P., Fenyvesi, F., Gáspár, R., Gunda, T., Hajdú, Z., Halmos, G., Herczegh, P., Hohmann, J., Lázár, L., Liktor-Busa, E., Nagymajtényi, L., Pál, S., Pálfi, M., Perjési, P., Soós, G., Szökő, É., Takács-Novák, K., Tábi, T., Tósaki, Á., Tóthfalusi, L., Zelkó, R., Zupkó, I., Váradi, J., Veres, K.: Általános gyógyszerészeti ismeretek.
Medicina Könyvkiadó Zrt., Budapest, 496 p., 2011. ISBN: 9789632429441

Rick, F., Schally, A., Block, N., Nadji, M., Szepesházi, K., Zarándi, M., Vidaurre, I., Perez, R., Halmos, G., Szalontay, L.: Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Proc. Natl. Acad. Sci. U. S. A. 108 (9), 3755-3760, 2011.

Mező, G., Szabó, I., Kertész, I., Hegedűs, R., Orbán, E., Leurs, U., Bősze, S., Halmos, G., Manea, M.: Efficient synthesis of an (aminooxy) acetylated-somatostatin derivative using (aminooxy)acetic acid as a 'carbonyl capture' reagent.
J. Pept. Sci. 17 (1), 39-46, 2011.

Steiber, Z., Treszl, A., Oláh, G., Buglyó, A., Rózsa, B., Berta, A., Halmos, G.: Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Human Uveal Melanomas.
Invest. Ophthalmol. Vis. Sci. 52 6021, 2011.

Kiss, C., Molnár, A., Treszl, A., Szegedi, I., Klekner, Á., Bognár, L., Dezső, B., Halmos, G.: Expression of receptors for luteinizing hormone-releasing hormone in pediatric neurogenic tumors.
Pediatr. Blood Cancer. 57 (5), 783, 2011.

Szilasi, M., Buglyó, A., Treszl, A., Kiss, L., Schally, A., Halmos, G.: Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Int. J. Oncol. 39 (4), 1019-1024, 2011.

Papadia, A., Schally, A., Halmos, G., Varga, J., Seitz, S., Buchholz, S., Rick, F., Zarándi, M., Bellyei, S., Treszl, A., Szalontay, L., Lucci, I.: Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer.
Horm. Metab. Res. 43 (11), 816-820, 2011.

Rick, F., Schally, A., Block, N., Halmos, G., Perez, R., Fernandez, J., Vidaurre, I., Szalontay, L.: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Prostate. 71 (7), 736-747, 2011.

Rózsa, B., Nadji, M., Schally, A., Dezső, B., Flaskó, T., Tóth, G., Mile, M., Block, N., Halmos, G.: Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) in Benign Prostatic Hyperplasia (BPH) as Potential Molecular Targets for Therapy with LHRH Antagonist Cetrorelix.
Prostate. 71 (5), 445-452, 2011.

Steiber, Z., Treszl, A., Rózsa, B., Berta, A., Halmos, G.: Receptors for luteinizing hormone-releasing hormone (LH-RH) in human uveal melanoma as potential molecular targets for cancer therapy.
Acta Ophthalmol. 88 S246, 2011.

Molnár, A., Szegedi, I., Rózsa, B., Mile, M., Halmos, G., Kiss, C.: Peptidhormon-receptorok kifejeződése lymphoma és leukemia sejtvonalakon, valamint gyermekkori lymphomás esetekben.
Hematol. Transzfuziol. 43 43, 2010.

Hohla, F., Buchholz, S., Schally, A., Krishan, A., Rick, F., Szalontay, L., Papadia, A., Halmos, G., Koster, F., Aigner, E., Datz, C., Seitz, S.: Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer Lett. 294 (1), 35-42, 2010.

Pozsgai, E., Schally, A., Halmos, G., Rick, F., Bellyei, S.: The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
Horm. Metab. Res. 42 (11), 781-786, 2010.

Rózsa, B., Juhász, A., Treszl, A., Tóth, G., Flaskó, T., Dezső, B., Block, N., Schally, A., Halmos, G.: Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
Int. J. Oncol. 35 (5), 1053-1059, 2009.

Molnár, A., Rózsa, B., Mile, M., Szegedi, I., Kiss, C., Halmos, G.: Expression of somatostatin receptors in childhood tumors and other malignancies.
Acta Physiol. Hung. 96 (1), 106-107, 2009.

Márka, M., Semjéni, M., Treszl, A., Tóth, G., Flaskó, T., Dezső, B., Halmos, G.: Expression of somatostatin receptor subtypes in human bladder carcinoma.
Acta Physiol. Hung. 96 (1), 100, 2009.

Mile, M., Juhász, B., Juhász, A., Dezső, B., Lukács, G., Halmos, G.: Expression of splice variants of luteinizing hormone-releasing hormone receptors in human colorectal cancers.
Acta Physiol. Hung. 96 (1), 105-106, 2009.

Hohla, F., Buchholz, S., Schally, A., Seitz, S., Rick, F., Szalontay, L., Varga, J., Zarándi, M., Halmos, G., Vidaurre, I., Krishan, A., Kurtoglu, M., Chandna, S., Aigner, E., Datz, C.: GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell Cycle. 8 (19), 3149-3156, 2009.

Treszl, A., Schally, A., Seitz, S., Szalontay, L., Rick, F., Szepesházi, K., Halmos, G.: Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Peptides. 30 (9), 1643-1650, 2009.

Halmos, G., Schally, A.: Peptide hormone receptors as new molecular targets in oncology.
Acta Physiol. Hung. 96 (1), 79-80, 2009.

Seitz, S., Schally, A., Treszl, A., Papadia, A., Rick, F., Szalontay, L., Szepesházi, K., Ortmann, O., Halmos, G., Hohla, F., Buchholz, S.: Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anticancer Drugs. 20 (7), 553-558, 2009.

Kertész, I., Pótári, N., Jószai, I., Semjéni, M., Rózsa, B., Galuska, L., Halmos, G.: The development of an 18F-labeled luteinising hormone-releasing hormone receptor targeting peptide ligand series.
Acta Physiol. Hung. 96 (1), 90-91, 2009.

Heinrich, E., Schally, A., Buchholz, S., Rick, F., Halmos, G., Mile, M., Groot, K., Hohla, F., Zarándi, M., Varga, J.: Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Prostate. 68 (16), 1763-1772, 2008.

Papadia, A., Schally, A., Seitz, S., Buchholz, S., Treszl, A., Szalontay, L., Halmos, G., Lucci, I.: Experimental therapy of ES-2 human platinum resistant ovarian cancer with targeted cytotoxic somatostatin and LHRH analogues.
Gynecol. Oncol. 111 (2), 376, 2008.

Juergen, E., Rózsa, B., Schally, A., Dezső, B., Tóth, G., Flaskó, T., Block, N., Nadji, M., Halmos, G.: Luteinizing Hormone-Releasing Hormone (LHRH) receptors in BPH as potential molecular targets for therapy with Cetrorelix.
J. Urol. 179 (4), 449-450, 2008.

Szepesházi, K., Schally, A., Treszl, A., Seitz, S., Halmos, G.: Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Anticancer Drugs. 19 (4), 349-358, 2008.

Mile, M., Huga, S., Juhász, A., Treszl, A., Hernádi, Z., Halmos, G.: Bombesin/gastrin-releasing peptid receptorok mint molekuláris célpontok az endometriumkarcinóma kezelésében.
Magyar Onkol. 51 (4), 364, 2007.

Hohla, F., Schally, A., Kanashiro, C., Buchholz, S., Baker, B., Kannadka, C., Moder, A., Aigner, E., Datz, C., Halmos, G.: Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Proc. Natl. Acad. Sci. U.S.A. 104 (47), 18671-18676, 2007.

Szepesházi, K., Schally, A., Halmos, G.: LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Int. J. Oncol. 30 (6), 1485-1492, 2007.

Buchholz, S., Schally, A., Engel, J., Hohla, F., Heinrich, E., Koester, F., Varga, J., Halmos, G.: Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proc. Natl. Acad. Sci. U.S.A. 104 1943-1946, 2007.

Semjéni, M., Treszl, A., Huga, S., Juhász, A., Hernádi, Z., Halmos, G.: Szomatosztatin receptorok expressziójan és ezek jelentősége a humán endometriumkarcinóma célzott terápiájában.
Magyar Onkol. 51 (4), 394, 2007.

Stangelberger, A., Schally, A., Zarándi, M., Heinrich, E., Groot, K., Havt, A., Kanashiro, C., Varga, J., Halmos, G.: The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Prostate. 67 (12), 1339-1353, 2007.

Halmos, G., Schally, A., Bernardino, A., Varga, J.: Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.
Int. J. Oncol. 29 (2), 463-469, 2006.

Keller, G., Schally, A., Nagy, A., Baker, B., Halmos, G., Engel, J.: Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Int. J. Oncol. 28 (6), 1507-1513, 2006.

Stangelberger, A., Schally, A., Nagy, A., Szepesházi, K., Kanashiro, C., Halmos, G.: Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Prostate. 66 (2), 200-210, 2006.

Zarándi, M., Varga, J., Schally, A., Horváth, J., Toller, G., Kovács, M., Letsch, M., Groot, K., Armatis, P., Halmos, G.: Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Proc. Natl. Acad. Sci. U. S. A. 103 (12), 4610-4615, 2006.

Hohla, F., Schally, A., Szepesházi, K., Varga, J., Buchholz, S., Köster, F., Heinrich, E., Halmos, G., Rick, F., Kannadka, C., Datz, C., Kanashiro, C.: Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proc. Natl. Acad. Sci. U. S. A. 103 (39), 14513-14518, 2006.

Buchholz, S., Keller, G., Schally, A., Halmos, G., Hohla, F., Heinrich, E., Koester, F., Baker, B., Engel, J.: Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proc. Natl. Acad. Sci. U. S. A. 103 (27), 10403-10407, 2006.

Kanashiro, C., Schally, A., Cai, R., Halmos, G.: Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Anti-Cancer Drugs. 16 (2), 159-165, 2005.

Stangelberger, A., Schally, A., Varga, J., Hammann, B., Groot, K., Halmos, G., Cai, R., Zarándi, M.: Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Prostate. 64 (3), 303-315, 2005.

Kanashiro, C., Schally, A., Varga, J., Hammann, B., Halmos, G., Zarándi, M.: Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Cancer Lett. 226 (2), 123-131, 2005.

Engel, J., Keller, G., Schally, A., Halmos, G., Hammann, B., Nagy, A.: Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clin. Cancer Res. 11 (6), 2408-2415, 2005.

Engel, J., Keller, G., Schally, A., Nagy, A., Chism, D., Halmos, G.: Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertil. Steril. Suppl. 83 (Suppl.), 1125-1133, 2005.

Keller, G., Schally, A., Groot, K., Toller, G., Havt, A., Köster, F., Armatis, P., Halmos, G., Zarándi, M., Varga, J., Engel, J.: Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proc. Natl. Acad. Sci. U. S. A. 102 (30), 10628-10633, 2005.

Engel, J., Schally, A., Halmos, G., Baker, B., Nagy, A., Keller, G.: Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
Eur. J. Cancer. 41 (12), 1824-1830, 2005.

Keller, G., Engel, J., Schally, A., Nagy, A., Hammann, B., Halmos, G.: Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Int. J. Cancer. 114 (5), 831-835, 2005.

Keller, G., Schally, A., Gaiser, T., Nagy, A., Baker, B., Westphal, G., Halmos, G., Engel, J.: Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer Res. 65 (13), 5857-5863, 2005.

Kanashiro, C., Schally, A., Nagy, A., Halmos, G.: Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
Int. J. Oncol. 27 (1), 169-174, 2005.

Szepesházi, K., Schally, A., Nagy, A., Halmos, G.: Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas. 31 (3), 275-282, 2005.

Engel, J., Keller, G., Schally, A., Toller, G., Groot, K., Havt, A., Armatis, P., Zarándi, M., Varga, J., Halmos, G.: Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
J. Clin. Endocrinol. Metab. 90 (6), 3614-3621, 2005.

Stangelberger, A., Schally, A., Varga, J., Zarándi, M., Szepesházi, K., Armatis, P., Halmos, G.: Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clin. Cancer Res. 11 (1), 49-57, 2005.

Lasfer, M., Vadrot, N., Schally, A., Nagy, A., Halmos, G., Pessayre, D., Feldmann, G., Reyl-Desmars, F.: Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
J. Hepatol. 42 (2), 230-237, 2005.

Keller, G., Schally, A., Gaiser, T., Nagy, A., Baker, B., Halmos, G., Engel, J.: Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
Eur. J. Cancer. 41 (14), 2196-2202, 2005.

Keller, G., Schally, A., Gaiser, T., Nagy, A., Baker, B., Halmos, G., Engel, J.: Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clin. Cancer Res. 11 (15), 5549-5557, 2005.

Keller, G., Schally, A., Nagy, A., Halmos, G., Baker, B., Engel, J.: Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer. 104 (10), 2266-2274, 2005.

Engel, J., Schally, A., Halmos, G., Baker, B., Nagy, A., Keller, G.: Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocr. Relat. Cancer. 12 (4), 999-1009, 2005.

Engel, J., Schally, A., Halmos, G., Baker, B., Nagy, A., Keller, G.: Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer. 104 (6), 1312-1321, 2005.

Havt, A., Schally, A., Halmos, G., Varga, J., Toller, G., Horváth, J., Szepesházi, K., Köster, F., Kovitz, K., Groot, K., Zarándi, M., Kanashiro, C.: The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proc. Natl. Acad. Sci. U. S. A. 102 (48), 17424-17429, 2005.

Toller, G., Horváth, J., Schally, A., Halmos, G., Varga, J., Groot, K., Chism, D., Zarándi, M.: Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Proc. Natl. Acad. Sci. U. S. A. 101 (42), 15160-15165, 2004.

Letsch, M., Schally, A., Szepesházi, K., Halmos, G., Nagy, A.: Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
J. Urol. 171 (2), 911-915, 2004.

Papadia, A., Schally, A., Seitz, S., Buchholz, S., Rick, F., Szalontay, L., Halmos, G., Treszl, A., Lucci, I.: Experimental therapy of ES-2 human platinum resistant ovarian cancer with growth hormone-releasing hormone antagonist JMR-132 or with targeted cytotoxic analog somatostatin AN-162.
Gynecol. Oncol. 112 (2), S128-S129, 2004.

Varga, J., Schally, A., Horváth, J., Kovács, M., Halmos, G., Groot, K., Toller, G., Rékási, Z., Zarándi, M.: Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Proc. Natl. Acad. Sci. U. S. A. 101 (6), 1708-1713, 2004.

Schally, A., Szepesházi, K., Nagy, A., Comaru-Schally, A., Halmos, G.: New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cell. Mol. Life Sci. 61 (9), 1042-1068, 2004.

Halmos, G., Schally, A., Comaru-Schally, A., Nagy, A., Irimpen, A.: Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
J. Investig. Med. Suppl. 51 (1), S527, 2003.

Halmos, G., Schally, A., Comaru-Schally, A., Nagy, A., Irimpen, A.: Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
Life Sci. 72 (23), 2669-2674, 2003.

Szereday, Z., Schally, A., Varga, J., Kanashiro, C., Hebert, F., Armatis, P., Groot, K., Szepesházi, K., Halmos, G., Busto, R.: Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer Res. 63 (22), 7913-7919, 2003.

Szereday, Z., Schally, A., Szepesházi, K., Bajo, A., Hebert, F., Halmos, G., Nagy, A.: Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Int. J. Oncol. 22 (5), 1141-1146, 2003.

Kiaris, H., Chatzistamou, I., Schally, A., Halmos, G., Varga, J., Koutselini, H., Kalofoutis, A.: Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proc. Natl. Acad. Sci. U. S. A. 100 (16), 9512-9517, 2003.

Letsch, M., Schally, A., Szepesházi, K., Halmos, G., Nagy, A.: Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clin. Cancer Res. 9 (12), 4505-4513, 2003.

Szepesházi, K., Schally, A., Nagy, A., Wagner, B., Bajo, A., Halmos, G.: Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer. 98 (7), 1401-1410, 2003.

Bajo, A., Schally, A., Halmos, G., Nagy, A.: Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Clin. Cancer Res. 9 (10), 3742-3748, 2003.

Halmos, G., Schally, A.: Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Proc. Natl. Acad. Sci. U. S. A. 99 (2), 961-965, 2002.

Plonowski, A., Schally, A., Nagy, A., Sun, B., Halmos, G.: Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Int. J. Oncol. 20 (2), 397-402, 2002.

Szereday, Z., Schally, A., Nagy, A., Plonowski, A., Bajo, A., Halmos, G., Szepesházi, K., Groot, K.: Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
Br. J. Cancer. 86 (8), 1322-1327, 2002.

Kiaris, H., Schally, A., Busto, R., Halmos, G., Artavanis-Tsakonas, S., Varga, J.: Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.
Proc. Natl. Acad. Sci. U. S. A. 99 (1), 196-200, 2002.

Plonowski, A., Schally, A., Busto, R., Krupa, M., Varga, J., Halmos, G.: Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Peptides. 23 (6), 1127-1133, 2002.

Halmos, G., Schally, A., Czompoly, T., Krupa, M., Varga, J., Rékási, Z.: Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
J. Clin. Endocrinol. Metab. 87 (10), 4707-4714, 2002.

Plonowski, A., Varga, J., Schally, A., Krupa, M., Groot, K., Halmos, G.: Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Int. J. Cancer. 98 (4), 624-629, 2002.

Szepesházi, K., Schally, A., Halmos, G., Armatis, P., Hebert, F., Sun, B., Feil, A., Kiaris, H., Nagy, A.: Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer res. 62 (3), 781-788, 2002.

Szepesházi, K., Schally, A., Armatis, P., Groot, K., Hebert, F., Feil, A., Varga, J., Halmos, G.: Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology. 142 (10), 4371-4378, 2001.

Chatzistamou, I., Schally, A., Varga, J., Groot, K., Armatis, P., Busto, R., Halmos, G.: Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
J. Clin. Endocrinol. Metab. 86 (5), 2144-2152, 2001.

Rékási, Z., Varga, J., Schally, A., Plonowski, A., Halmos, G., Csernus, B., Armatis, P., Groot, K.: Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides. 22 (6), 879-886, 2001.

Kiaris, H., Schally, A., Nagy, A., Szepesházi, K., Hebert, F., Halmos, G.: A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
Eur. J. Cancer. 37 (5), 620-628, 2001.

Schally, A., Comaru-Schally, A., Nagy, A., Kovács, M., Szepesházi, K., Plonowski, A., Varga, J., Halmos, G.: Hypothalamic hormones and cancer.
Front. Neuroendocrinol. 22 (4), 248-291, 2001.

Chatzistamou, I., Schally, A., Varga, J., Groot, K., Busto, R., Armatis, P., Halmos, G.: Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.
Anti-Cancer Drugs. 12 (9), 761-768, 2001.

Plonowski, A., Schally, A., Koppán, M., Nagy, A., Arencibia, J., Csernus, B., Halmos, G.: Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Cancer. 92 (5), 1168-1176, 2001.

Arencibia, J., Schally, A., Halmos, G., Nagy, A., Kiaris, H.: In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Anticancer Drugs. 12 (1), 71-78, 2001.

Szepesházi, K., Schally, A., Halmos, G., Sun, B., Hebert, F., Csernus, B., Nagy, A.: Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clin. Cancer. Res. 7 (9), 2854-2861, 2001.

Schally, A., Halmos, G., Rékási, Z., Arencibia-Jimenez, J.: The actions of Luteinizing hormone-releasing hormone agonists, antagonosts, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors.
In: Infertility and Reproductive Medicine. Ed.: Paul Devroey, W. B. Saunders Company, USA, 17-44, 2001.

Kahán, Z., Nagy, A., Schally, A., Halmos, G., Arencibia, J., Groot, K.: Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Breast Cancer Res. Treat. 59 (3), 255-262, 2000.

Rékási, Z., Varga, J., Schally, A., Halmos, G., Groot, K., Czompoly, T.: Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Proc. Natl. Acad. Sci. U. S. A. 97 (3), 1218-1223, 2000.

Szepesházi, K., Schally, A., Groot, K., Armatis, P., Halmos, G., Hebert, F., Szende, B., Varga, J., Zarándi, M.: Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
Br. J. Cancer. 82 (10), 1724-1731, 2000.

Szepesházi, K., Schally, A., Groot, K., Armatis, P., Hebert, F., Halmos, G.: Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
Eur. J. Cancer. 36 (1), 128-136, 2000.

Rékási, Z., Varga, J., Schally, A., Halmos, G., Armatis, P., Groot, K., Czompoly, T.: Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Endocrinology. 141 (6), 2120-2128, 2000.

Kahán, Z., Varga, J., Schally, A., Rékási, Z., Armatis, P., Chatzistamou, I., Czömpöly, T., Halmos, G.: Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Breast Cancer Res. Treat. 60 (1), 71-79, 2000.

Halmos, G., Schally, A., Kahán, Z.: Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Int. J. Oncol. 17 (2), 367-373, 2000.

Chatzistamou, I., Schally, A., Nagy, A., Armatis, P., Szepesházi, K., Halmos, G.: Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clin. Cancer Res. 6 (10), 4158-4165, 2000.

Halmos, G., Schally, A., Sun, B., Davis, R., Bostwick, D., Plonowski, A.: High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
J. Clin. Endocrinol. Metab. 85 (7), 2564-2571, 2000.

Halmos, G., Arencibia, J., Schally, A., Davis, R., Bostwick, D.: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
J. Urol. 163 (2), 623-629, 2000.

Halmos, G., Sun, B., Schally, A., Hebert, F., Nagy, A.: Human ovarian cancers express somatostatin receptors.
J. Clin. Endocrinol. Metab. 85 (10), 3509-3512, 2000.

Halmos, G., Schally, A., Varga, J., Plonowski, A., Rékási, Z., Czompoly, T.: Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proc. Natl. Acad. Sci. U.S.A. 97 (19), 10555-10560, 2000.

Kahán, Z., Sun, B., Schally, A., Arencibia, J., Cai, R., Groot, K., Halmos, G.: Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Cancer. 88 (6), 1384-1392, 2000.

Plonowski, A., Schally, A., Nagy, A., Kiaris, H., Hebert, F., Halmos, G.: Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Cancer Res. 60 (11), 2996-3001, 2000.

Plonowski, A., Nagy, A., Schally, A., Sun, B., Groot, K., Halmos, G.: In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
Int. J. Cancer. 88 (4), 652-657, 2000.

Rékási, Z., Czompoly, T., Schally, A., Halmos, G.: Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.
Proc. Natl. Acad. Sci. U.S.A. 97 (19), 10561-10566, 2000.

Schally, A., Comaru-Schally, A., Plonowski, A., Nagy, A., Halmos, G., Rékási, Z.: Peptide analogs in the therapy of prostate cancer.
Prostate. 45 (2), 158-166, 2000.

Plonowski, A., Schally, A., Varga, J., Rékási, Z., Hebert, F., Halmos, G., Groot, K.: Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Prostate. 44 (2), 172-180, 2000.

Sun, B., Halmos, G., Schally, A., Wang, X., Martinez, M.: Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
Prostate. 42 (4), 295-303, 2000.

Kiaris, H., Schally, A., Nagy, A., Sun, B., Szepesházi, K., Halmos, G.: Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clin. Cancer Res. 6 (2), 709-717, 2000.

Sun, B., Schally, A., Halmos, G.: The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.
Regul. Pept. 90 (1-3), 77-84, 2000.

Kahán, Z., Nagy, A., Schally, A., Halmos, G., Arencibia, J., Groot, K.: Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Cancer. 85 (12), 2608-2615, 1999.

Halmos, G., Nagy, A., Lamharzi, N., Schally, A.: Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Cancer Lett. 136 (2), 129-136, 1999.

Szepesházi, K., Halmos, G., Schally, A., Arencibia, J., Groot, K., Vadillo-Buenfil, M., Rodriguez-Martin, E.: Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
J. Cancer Res. Clin. Oncol. 125 (8-9), 444-452, 1999.

Varga, J., Schally, A., Csernus, V., Zarándi, M., Halmos, G., Groot, K., Rékási, Z.: Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Proc. Natl. Acad. Sci. U. S. A. 96 (2), 692-697, 1999.

Miyazaki, M., Schally, A., Nagy, A., Lamharzi, N., Halmos, G., Szepesházi, K., Armatis, P.: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
Am. J. Obstet. Gynecol. 180 (5), 1095-1103, 1999.

Koppán, M., Nagy, A., Schally, A., Plonowski, A., Halmos, G., Arencibia, J., Groot, K.: Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Inhibits the Growth of PC-82 Human Prostate Cancer in Nude Mice.
Prostate. 38 (2), 151-158, 1999.

Koppán, M., Halmos, G., Arencibia, J., Lamharzi, N., Schally, A.: Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Cancer. 83 (7), 1335-1343, 1998.

Lamharzi, N., Halmos, G., Jungwirth, A., Schally, A.: Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Int. J. Oncol. 13 (3), 429-435, 1998.

Miyazaki, M., Lamharzi, N., Schally, A., Halmos, G., Szepesházi, K., Groot, K., Cai, R.: Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
Eur. J. Cancer. 34 (5), 710-717, 1998.

Jungwirth, A., Schally, A., Halmos, G., Groot, K., Szepesházi, K., Pinski, J., Armatis, P.: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Cancer. 82 (5), 909-917, 1998.

Tóth, K., Kovács, M., Zarándi, M., Halmos, G., Groot, K., Nagy, A., Kele, Z., Schally, A.: New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
J. Pept. Res. 51 (2), 134-141, 1998.

Jungwirth, A., Frick, J., Schally, A., Halmos, G., Groot, K., Szepesházi, K., Pinski, J.: Somatostatin analog RC-160, LH-RH antagonist cetrorelix and bombesin antagonist RC-3940-II inhibit growth of Caki-1 human renal carcinoma.
J. Urol. Suppl. S. 159 (5), 1998.

Nagy, A., Schally, A., Halmos, G., Armatis, P., Cai, R., Csernus, V., Kovács, M., Koppán, M., Szepesházi, K., Kahán, Z.: Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proc. Natl. Acad. Sci. U. S. A. 95 (4), 1794-1799, 1998.

Zarándi, M., Kovács, M., Horváth, J., Halmos, G., Groot, K., Schally, A.: Synthesis and in vitro biological activities of new potent GH-RH antagonists with citrulline substitutions.
In: Peptides 1996 : Proceedings of the Twenty-Fourth European Peptide Symposium, September 8-13, 1996, Edinburg, Scotland. Eds.: by Robert Ramage, Roger Epton, [S.n.], [S.l], 933-934, 1998.

Koppán, M., Nagy, A., Schally, A., Arencibia, J., Plonowski, A., Halmos, G.: Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Cancer res. 58 (18), 4132-4137, 1998.

Szepesházi, K., Schally, A., Halmos, G., Lamharzi, N., Groot, K., Horváth, J.: A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Proc. Natl. Acad. Sci. U. S. A. 94 (20), 10913-10918, 1997.

Nagy, A., Armatis, P., Cai, R., Szepesházi, K., Halmos, G., Schally, A.: Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proc. Natl. Acad. Sci. U. S. A. 94 (2), 652-656, 1997.

Jungwirth, A., Frick, J., Pinski, J., Halmos, G., Schally, A.: Growth hormone-releasing hormone (GH-RH) antagonist MZ-4-71 inhibits growth of Caki-I renal adenocarcinoma in nude mice.
In: 1997 Annual Meeteing New Orleans, LA, deadline for submitting papers is October 14, 1996.. Ed.: American Urological Association, [S. n.], [S.l.], , 1997.

Jungwirth, A., Schally, A., Pinski, J., Groot, K., Armatis, P., Halmos, G.: Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
Proc. Natl. Acad. Sci. U. S. A. 94 (11), 5810-5813, 1997.

Miyazaki, M., Nagy, A., Schally, A., Lamharzi, N., Halmos, G., Szepesházi, K., Groot, K., Armatis, P.: Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
J. Natl. Cancer Inst. 89 (23), 1803-1809, 1997.

Jungwirth, A., Pinski, J., Galvan, G., Halmos, G., Szepesházi, K., Cai, R., Groot, K., Vadillo-Buenfil, M., Schally, A.: Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Eur. J. Cancer. 33 (7), 1141-1148, 1997.

Jungwirth, A., Galvan, G., Pinski, J., Halmos, G., Szepesházi, K., Cai, R., Groot, K., Schally, A.: Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Prostate. 32 (3), 164-172, 1997.

Halmos, G., Schally, A.: Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Proc. Natl. Acad. Sci. U. S. A. 94 (3), 956-960, 1997.

Jungwirth, A., Schally, A., Nagy, A., Pinski, J., Groot, K., Galvan, G., Szepesházi, K., Halmos, G.: Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.
Int. J. Oncol. 10 (5), 877-884, 1997.

Zarándi, M., Kovács, M., Horváth, J., Tóth, K., Halmos, G., Groot, K., Nagy, A., Kele, Z., Schally, A.: Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides. 18 (3), 423-430, 1997.

Szepesházi, K., Schally, A., Nagy, A., Halmos, G., Groot, K.: Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anticancer Drugs. 8 (10), 974-987, 1997.

Kovács, M., Halmos, G., Groot, K., Izdebski, J., Schally, A.: Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.
Neuroendocrinology. 64 (3), 169-176, 1996.

Pinski, J., Lamharzi, N., Halmos, G., Groot, K., Jungwirth, A., Vadillo-Buenfil, M., Kakar, S., Schally, A.: Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Endocrinology. 137 (8), 3430-3436, 1996.

Nagy, A., Schally, A., Armatis, P., Szepesházi, K., Halmos, G., Kovács, M., Zarándi, M., Groot, K., Miyazaki, M., Jungwirth, A., Horváth, J.: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proc. Natl. Acad. Sci. U. S. A. 93 (14), 7269-7273, 1996.

Halmos, G., Schally, A., Pinski, J., Vadillo-Buenfil, M., Groot, K.: Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Proc. Natl. Acad. Sci. U. S. A. 93 (6), 2398-2402, 1996.

Szepesházi, K., Schally, A., Halmos, G., Szőke, B., Groot, K., Nagy, A.: Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast Cancer Res. Treat. 40 (2), 129-139, 1996.

Kovács, M., Zarándi, M., Halmos, G., Groot, K., Schally, A.: Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Endocrinology. 137 (12), 5364-5369, 1996.

Szepesházi, K., Schally, A., Cai, R., Halmos, G., Groot, K.: Effects of new bombesin antagonists given singly or in combination with a somatostatin analog on nitrosamine-induced pancreatic cancers in hamsters.
Int. J. Oncol. 9 (3), 397-403, 1996.

Pinski, J., Schally, A., Jungwirth, A., Groot, K., Halmos, G., Armatis, P., Zarándi, M., Vadillo-Buenfil, M.: Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).
Int. J. Oncol. 9 (6), 1099-1105, 1996.

Pinski, J., Schally, A., Halmos, G., Szepesházi, K., Groot, K.: Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice.
Int. J. Cancer. 65 (6), 870-874, 1996.

Thakur, M., Kolan, H., Rifat, S., Li, J., Rux, A., John, E., Halmos, G., Schally, A.: Vapreotide labeled with Tc-99m for imaging tumors: preparation and preliminary evaluation.
Int. J. Oncol. 9 (3), 445-451, 1996.

Halmos, G., Wittliff, J., Schally, A.: Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
Cancer Res. 55 (2), 280-287, 1995.

Thakur, M., Kolan, H., Li, J., Duggaraju, R., Halmos, G., Schally, A.: Imaging breast-cancer with tc-99m-somatostatin analogs rc-160 and sandostatin: comparison with in-111 octreotide.
Radiology. Suppl. 197 (Suppl.), 320, 1995.

Pinski, J., Schally, A., Groot, K., Halmos, G., Szepesházi, K., Zarándi, M., Armatis, P.: Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
J. Natl. Cancer Inst. 87 (23), 1787-1794, 1995.

Schally, A., Nagy, A., Szepesházi, K., Pinski, J., Halmos, G., Armatis, P., Miyazaki, M., Comaru-Schally, A., Yano, T., Emons, G.: LHRH analogs with cytotoxic radicals.
In: Treatment with GnRH Analogues / [eds. Roger D. Kempers ... et al], [S.n.], [S.l.], 33-44, 1995.

Izdebski, J., Pinski, J., Horváth, J., Halmos, G., Groot, K., Schally, A.: Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.
Proc. Natl. Acad. Sci. U. S. A. 92 (11), 4872-4876, 1995.

Thakur, M., John, E., Li, J., Reddy, H., Halmos, G., Schally, A.: TC-99M-RC-160: a somatostatin analog for imaging prostate cancer : comparison with I-125-RC-160 and IN-111 octreotide.
J. Nucl. Med. 36 92, 1995.

Schally, A., Halmos, G., Pinski, J.: Terminology for luteinizing-hormone-releasing hormone antagonists.
Fertil. Steril. 64 (1), 226, 1995.

Schally, A., Pinski, J., Szepesházi, K., Yano, T., Halmos, G., Shirahige, Y., Comaru-Schally, A., Cai, R., Nagy, A.: Antitumor effects of analogs of LH-RH, somatostatin and bombesin/GRP in experimental models of breast and prostate cancer.
J. Cell. Biochem. 18D 222, 1994.

Schally, A., Szepesházi, K., Qin, Y., Halmos, G., Ertl, T., Groot, K., Cai, R., Liebow, C., Poston, G.: Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer.
Int. J. Pancreatol. 16 (2-3), 246-249, 1994.

Szepesházi, K., Schally, A., Halmos, G.: Apoptosis in pancreatic cancers of hamsters.
Int J. Pancreatol. 16 (2-3), 282-287, 1994.

Qin, Y., Halmos, G., Cai, R., Szőke, B., Ertl, T., Schally, A.: Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
J. Cancer Res. Clin. Oncol. 120 (9), 519-528, 1994.

Halmos, G., Pinski, J., Szőke, B., Schally, A.: Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.
Cancer Lett. 85 (1), 111-118, 1994.

Szepesházi, K., Halmos, G., Groot, K., Schally, A.: Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
Int. J. Pancreatol. 16 (2-3), 141-149, 1994.

Schally, A., Nagy, A., Cai, R., Reile, H., Radulovic, S., Qin, Y., Szepesházi, K., Halmos, G., Comaru-Schally, A.: Combined hormonal therapy and chemotherapy for pancreatic cancer; use of cytotoxic peptide analogs for targeted chemotherapy.
Int. J. Pancreatol. 16 (2-3), 277-280, 1994.

Pinski, J., Schally, A., Halmos, G., Szepesházi, K., Groot, K., O'Byrne, K., Cai, R.: Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Br. J. Cancer. 70 (5), 886-892, 1994.

Pinski, J., Halmos, G., Yano, T., Szepesházi, K., Qin, Y., Ertl, T., Schally, A.: Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
Int. J. Cancer. 57 (4), 574-580, 1994.

Yano, T., Pinski, J., Halmos, G., Szepesházi, K., Groot, K., Schally, A.: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proc. Natl. Acad. Sci. U. S. A. 91 (15), 7090-7094, 1994.

Shirahige, Y., Cai, R., Szepesházi, K., Halmos, G., Pinski, J., Groot, K., Schally, A.: Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Biomed. Pharmacother. 48 (10), 465-472, 1994.

Yano, T., Pinski, J., Szepesházi, K., Halmos, G., Radulovic, S., Groot, K., Schally, A.: Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Cancer. 73 (4), 1229-1238, 1994.

Qin, Y., Ertl, T., Cai, R., Halmos, G., Schally, A.: Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Cancer Res. 54 (4), 1035-1041, 1994.

Pinski, J., Reile, H., Halmos, G., Groot, K., Schally, A.: Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Int. J. Cancer. 59 (1), 51-55, 1994.

Radulovic, S., Schally, A., Reile, H., Halmos, G., Szepesházi, K., Groot, K., Milovanovic, S., Miller, G., Yano, T.: Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
Acta Oncol. 33 (6), 693-701, 1994.

Pinski, J., Reile, H., Halmos, G., Groot, K., Schally, A.: Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Cancer Res. 54 (1), 169-174, 1994.

Szőke, B., Horváth, J., Halmos, G., Rékási, Z., Groot, K., Nagy, A., Schally, A.: LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
Peptides. 15 (2), 359-366, 1994.

Pinski, J., Schally, A., Halmos, G., Szepesházi, K., Groot, K.: Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Cancer Res. 54 (22), 5895-5901, 1994.

Thakur, M., Halmos, G., Jan, J., John, E., Li, J., Mayo, K., Rifat, S., Rux, A., Varnum, J., Wilder, S., Schally, A.: Technetium-99m rc-160: a somatostatin analogue (1063).
J. Nucl. Med. 35 (5), 259, 1994.

Szende, B., Csikós, A., Szepesházi, K., Neill, J., Mulchahey, J., Halmos, G., Lapis, K., Schally, A.: The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells: effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
Receptor. 4 (4), 201-207, 1994.

Shirahige, Y., Cook, C., Pinski, J., Halmos, G., Nair, R., Schally, A.: Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice.
Int. J. Oncol. 5 (5), 1031-1035, 1994.

Pinski, J., Halmos, G., Szepesházi, K., Schally, A.: Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Cancer. 72 (11), 3263-3270, 1993.

Szepesházi, K., Schally, A., Groot, K., Halmos, G.: Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Int. J. Cancer. 54 (2), 282-289, 1993.

Pinski, J., Schally, A., Halmos, G., Szepesházi, K.: Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
Int. J. Cancer. 55 (6), 963-967, 1993.

Pinski, J., Schally, A., Yano, T., Szepesházi, K., Halmos, G., Groot, K., Comaru-Schally, A., Radulovic, S., Nagy, A.: Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
Prostate. 23 (2), 165-178, 1993.

Pinski, J., Halmos, G., Shirahige, Y., Wittliff, J., Schally, A.: Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.
J. Clin. Endocrinol. Metab. 77 (5), 1388-1392, 1993.

Pinski, J., Halmos, G., Schally, A.: Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Cancer Lett. 71 (1-3), 189-196, 1993.

Halmos, G., Rékási, Z., Szőke, B., Schally, A.: Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone.
Receptor. 3 (2), 87-97, 1993.

Szepesházi, K., Schally, A., Halmos, G., Groot, K., Radulovic, S.: Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
J. Natl. Cancer Inst. 84 (24), 1915-1922, 1992.

Janáky, T., Juhász, A., Rékási, Z., Serfőző, P., Pinski, J., Bokser, L., Srkalovic, G., Milovanovic, S., Redding, T., Halmos, G., Nagy, A., Schally, A.: Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
Proc. Natl. Acad. Sci. U. S. A. 89 (21), 10203-10207, 1992.

Halmos, G., Thurzó, L., Falkay, G.: A szteroid receptorok analízisének jelentősége a nőgyógyászati tumorok diagnosztikájában és terápiájában.
Gyógyszerészet. 34 181-183, 1990.